41. RESEARCH ON ANTIBIOTIC CONSUMPTION SITUATION IN THE TREATMENT OF COMMUNITY - ACQUIRED PNEUMONIA IN CHILDREN AT THE DEPARTMENT OF PEDIATRICS, QUANG NAM CENTRAL GENERAL HOSPITAL
Main Article Content
Abstract
Objective: To analyze the consumption of antibiotics in the treatment of community-acquired pneumonia (CAP) at the Department of Pediatrics, Quang Nam Central General Hospital in 2023.
Subject and method: A quantitative analysis based on the number of days of antibiotic use (DOT) and the length of antibiotic treatment (LOT) through a retrospective review of medical records of pediatric in-patients at the Department of Pediatrics during January 1st to December 31st, 2023 with diagnosis of pneumonia and excluding cases of hospital-acquired pneumonia
Results: A total of 416 medical records were included in this study. The average number of days of antibiotic use was 115.9 DOT/100 patient-days. The length of antibiotic treatment was almost equal to the length of hospitalization (88.0 LOT/100 patient-days). The frequently used regimens for initial empirical therapy were combination antibiotic therapy, with DOT/LOT ratios ranging from 1.1 to 1.6. The three groups of antibiotics with the highest consumption were C3G, penicillin/β-lactamase inhibitors, and aminoglycosides, of which, ceftriaxone was the most consumed antibiotic (29.8%).
Conclusion: The consumption of antibiotics in the treatment of CAP in the Department of Pediatrics was relatively high, the duration of antibiotic use was long and preferred combination regimens. Further in-depth analysis of problems related to antibiotic use in the treatment of pediatric CAP is needed, thereby implementing interventions to improve the quality of antibiotic use in hospitals.
Article Details
Keywords
community-acquired pneumonia, children, antibiotics, DOT, LOT
References
[2] Freja C.B.M., et al. Poor compliance with antimicrobial guidelines for childhood pneumonia. Danish Medical Journal. 2018; 65(11):A5516.
[3] Klein E.Y., et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 2018; 115: E3463– E70, doi: 10.1073/pnas.1717295115.
[4] Tran Quang Khai, et al. Antibiotic resistance of Streptococcus pneumonia in Vietnamese children with severe pneumonia: a cross-sectional study. Frontiers in Public Heath. 2023; 11: 1110903, doi: 10.3389/fpubh.2023.1110903.
[5] Nguyễn Thị Hải Yến và cộng sự. Bộ tiêu chí đánh giá Chương trình quản lý sử dụng kháng sinh tại bệnh viện. 2023. NXB Y học.
[6] Monique E., et al. Drug Utilization Research: Methods and Applications. 2016. Wiley & Sons, Ltd.
[7] Hoàng Minh Anh. Phân tích thực trạng sử dụng kháng sinh trong điều trị viêm phổi mắc phải cộng đồng ở trẻ em dưới 5 tuổi và một số yếu tố liên quan tại bệnh viện E Trung ương năm 2021 – 2022. Khóa luận tốt nghiệp Dược sĩ, Đại học Dược Hà Nội. 2023.
[8] Nguyễn Trọng Nghĩa. Phân tích tình hình sử dụng kháng sinh trên bệnh nhân điều trị nội trú tại Trung tâm Y tế huyện Văn Chấn tỉnh Yên Bái. Luận văn chuyên khoa cấp 1, Đại học Dược Hà Nội. 2023.
[9] Bruce R.D., et al. Antimicrobial use over a four-year period using days of therapy measurement at a Canadian pediatric acute care hospital. Can J Infect Med Microbiol. 2015; 26(5): 253-258, doi: 10.1155/2015/835209.
[10] Kariuki S., et al. Antibacterial resistance in sub-Saharan Africa: an underestimated emergency. Ann N Y Acad Sci. 2014; 1323(1): 43-55, doi: 10.1111/nyas.12380.
[11] Nguyễn Thành Hải và cộng sự. Thực trạng sử dụng kháng sinh trong điều trị viêm phổi mắc phải tại cộng đồng ở trẻ em từ 2 tháng đến 5 tuổi tại Bệnh viện Sản nhi Nghệ An năm 2022. Tạp chí Y dược lâm sàng 108. 2023. 18:218-225.
[12] Phuong T.K.N., et al. The dilemma of improving rational antibiotic use in pediatric community-acquired pneumonia. Frontiers in Pediatrics. 2023; 11: 1095166, doi: 10.3389/fped.2023.1095166.
[13] James S.N., et al. Inappropriate treatment of community-acquired pneumonia among children under five years of age in Tanzania. International Journal of Infectious Diseases. 2020; 93: 56-61, doi: 10.1016/j.ijid.2020.01.038.